ChemDiv signs drug discovery collaboration deal with Cystic Fibrosis Foundation Therapeutics

The agreement enables CFFT to use ChemDiv’s unique chemistry platform to advance promising scientific research in the field of cystic fibrosis (CF) treatment.

This collaboration allows ChemDiv to assist the largest CF clinical trials network in the world and contribute to the development of a lifelong cure for cystic fibrosis.

Cystic fibrosis is the most common autosomal disease, threatening the lives of its victims due to its progressive destruction of lungs. Patients frequently succumb to persistent lung infections as children or young adults. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with the disease worldwide and approximately 1,000 new cases of CF are diagnosed in the U.S. alone each year.

ChemDiv is one of the industry’s most experienced CROs and is a recognized global leader in discovery chemistry. ChemDiv has an exceptionally large, diverse, and pharmacologically-relevant library of molecules, with a commercial collection of over 1,600,000 individually crafted, lead-like, drug-like small molecules.

According to the agreement, ChemDiv will provide discovery chemistry services to CFFT for their innovative research programs aimed at the development of lifesaving new therapies for cystic fibrosis.

"ChemDiv’s unique drug discovery and evaluation platforms will provide CFFT with an excellent jumpstart for the identification of multiple novel therapeutic targets," said Nikolay Savchuk, CEO of ChemDiv.

"We are proud to be a part of CFFT’s exceptional research and development efforts to find a cure for this lethal genetic disease and save the lives of thousands of people around the globe."